Cardiovascular

If the full FDA accepts the panel's narrow recommendation, the type 2 diabetes therapy could enjoy a preferred status above its rivals in the SGLT2 market.

The study comes as regulators put increased emphasis on long-term cardiovascular outcomes trials to ensure safety of diabetes and obesity therapies. The American Journal of Managed Care recently convened an expert panel on the topic.

Reducing lipid levels in high-risk patients can significantly reduce disease burden and, depending on final negotiated prices, PCSK9 inhibitors can make an economic contribution to this goal.